The Health Technology Assessment Environment in Mainland China, Japan, South Korea, and Taiwan—Implications for the Evaluation of Diabetes Mellitus Therapies☆
Under an Elsevier user license
open archive
Keywords
Asia
diabetes mellitus
health technology assessment
pricing
reimbursement
Cited by (0)
- ☆
Conflict of interest: B.D. Mitchell, K.S. Boye, B.H. Curtis, J.A. Flynn, L. Liu, and E. Papadimitropoulos are employees of Eli Lilly. B.H. Curtis, K.S. Boye, E. Papadimitropoulous, J.A. Flynn and B.D. Mitchell are shareholders.
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.